Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053355 | 0.82 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20827784 | 0.77 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20827673 | 0.74 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24995564 | 0.73 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10281633 | 0.72 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBMKNK1 | |
| SCHEMBL20827732 | 0.72 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20827757 | 0.72 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20782409 | 0.72 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14667014 | 0.72 | PI4KB (0.39) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14667015 | 0.72 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20220177491-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2022-06-09 | — | — | US | disclosed |
| US-11130767-B2 | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247820-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-08-06 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130261101-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2013-10-03 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | PI4KA 183/4885PI4K2B 544/4885PI4K2A 609/4885 |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | PI4KA 1441/4885PI4K2B 2122/4885PI4K2A 2286/4885 |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-20200247820-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R1 | PI4KA 14/4885PI4K2B 17/4885PI4K2A 27/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | PI4KA 1441/4885PI4K2B 2122/4885PI4K2A 2286/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | PI4KA 1441/4885PI4K2B 2122/4885PI4K2A 2286/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | PI4KA 1544/4885PI4K2B 1526/4885PI4K2A 1250/4885 |
| US-20130261101-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CB | PI4KA 10/4885PI4K2B 14/4885PI4K2A 20/4885 |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | RIPK1, RIPK3, RIPK4 | PI4KA 532/4885PI4K2B 642/4885PI4K2A 541/4885 |
| US-11130767-B2 | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | PIK3CA, PIK3CD, PIK3R1 | PI4KA 14/4885PI4K2B 17/4885PI4K2A 27/4885 |
| US-20220177491-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R1 | PI4KA 14/4885PI4K2B 18/4885PI4K2A 27/4885 |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.